Notice of
Annual General Meeting 2017

ORORA LIMITED
ACN 004 275 165

Tuesday 17 October 2017 at 10.30am
(Melbourne Time)
Hawthorn Arts Centre
360 Burwood Road
Hawthorn VIC Australia
15 September 2017

Dear Shareholder

On behalf of the Board of Directors, I am pleased to invite you to attend the fourth Annual General Meeting of Orora Limited, which will be held at 10.30am (Melbourne Time) on Tuesday 17 October 2017 at the Hawthorn Arts Centre, 360 Burwood Road, Hawthorn, Victoria. Directions to the venue can be found inside the back cover of this notice.

If you are unable to attend the meeting, you are encouraged to lodge your vote in advance by completing the Proxy Form enclosed with this Notice of Meeting and returning it in the envelope provided, or by fax to the number on the Proxy Form. Alternatively, the Proxy Form can be lodged electronically by visiting www.ororagroup.com and clicking on “AGM Proxy Voting” and following the instructions provided. To gain access to the voting site, you will need your holder identifier (SRN or HIN) and postcode.

Shareholders attending the AGM can register from 9.30am (Melbourne Time) at the venue. If you will be attending in person, please bring your Proxy Form to assist with your registration at the meeting.

Shareholders will have an opportunity to meet with Directors and senior executives, prior to, and at the conclusion of, the meeting. Light refreshments will also be available.

If you wish to submit a question to me or Orora’s Auditor in advance of the meeting, you can complete this online at www.ororagroup.com by clicking on “AGM Proxy Voting”, or by sending your question to Orora Limited, C/- Link Market Services Limited, Locked Bag A14, Sydney South NSW 1235. Questions should be received by no later than 5.00pm (Melbourne Time) on Tuesday 10 October 2017. We will endeavor to respond to as many of the more frequently asked questions as possible at the meeting.

The Annual Report can be viewed online at http://www.ororagroup.com/investors/downloads/annual-reports

Orora’s website also offers shareholders details of the latest share price, announcements made to the ASX, investor and analyst presentations and many other publications that may be of interest.

You can also keep up-to-date with Orora news and announcements by downloading the Orora app. Visit the Apple App Store or Google Play Store, search for “Orora” and install the app onto your device. The app is free and can be downloaded to most smartphones or tablets. To access the newsfeed simply tap “Skip to news” on the bottom of the home screen.

On behalf of the Board, I thank you for your continued support as a shareholder of Orora Limited. I look forward to your attendance at the meeting.

Yours faithfully

Chris Roberts
Chairman

Invitation from the Chairman
Notice of Annual General Meeting 2017

Notice is hereby given that the fourth Annual General Meeting of Orora Limited ACN 004 275 165 (the “Company”) will be held at the Hawthorn Arts Centre, 360 Burwood Road, Hawthorn, Victoria on Tuesday 17 October 2017 at 10.30am (Melbourne Time).

Business of the Meeting

1. Financial Statements and Reports
   To receive and consider the Financial Statements of the Company and the Reports of the Directors and the Auditor of the Company for the financial year ended 30 June 2017.

2. Re-election of Directors
   To consider and, if thought fit, pass the following resolutions as ordinary resolutions:
   a. To re-elect as a Director Ms Abi Cleland, who retires by rotation in accordance with the Company’s Constitution and the ASX Listing Rules and, being eligible, offers herself for re-election.
   b. To re-elect as a Director Mr John Pizzey, who retires by rotation in accordance with the Company’s Constitution and the ASX Listing Rules and, being eligible, offers himself for re-election.

3. Incentive grants to Managing Director and Chief Executive Officer
   To consider and, if thought fit, pass the following resolutions as ordinary resolutions:
   a. That approval is given for the purposes of ASX Listing Rule 10.14 and for all other purposes for the grant of Deferred Performance Rights to the Managing Director and Chief Executive Officer of the Company, Mr Nigel Garrard, in accordance with the rules of the Company’s short term incentive plan in respect of the financial year ending 30 June 2018, on the terms summarised in the Explanatory Notes.
   b. That approval is given for the purposes of ASX Listing Rule 10.14 and for all other purposes for the grant of 1,305,000 Options and 342,000 Performance Rights to the Managing Director and Chief Executive Officer of the Company, Mr Nigel Garrard, in accordance with the rules of the Company’s long term incentive plan on the terms summarised in the Explanatory Notes.

Voting exclusions
Under the ASX Listing Rules and the Corporations Act 2001 (Cth) (“Corporations Act”), the following persons may not vote, and the Company will disregard any votes cast by or on behalf of the following persons, on the resolutions in items 3(a) and 3(b):
   • Mr Nigel Garrard or any of his associates; and
   • any member of Orora’s key management personnel (“KMP”) as at the date of the Annual General Meeting (or any closely related party of a KMP) who is appointed as a proxy.

However, these exclusions will not apply where the vote is cast by:
   • a person as proxy for a person who is entitled to vote, provided that the vote is cast in accordance with a direction on the proxy form as to how the proxy is to vote on items 3(a) and 3(b); or
   • the Chairman of the Annual General Meeting as proxy for a person who is entitled to vote, and the proxy appointment expressly authorises the Chairman to vote undirected proxies on the resolutions in items 3(a) and 3(b) as the Chairman decides.

Dated: 15 September 2017
By order of the Board

Ann Stubbings
Company Secretary
Orora Limited

4. Remuneration Report
   To consider and, if thought fit, pass the following resolution as an advisory ordinary resolution:
   To adopt the Remuneration Report of the Company for the financial year ended 30 June 2017.
   Please note that this resolution is advisory only and does not bind the Directors or the Company.

Voting exclusions
Under the Corporations Act, the following persons may not vote, and the Company will disregard any votes cast by or on behalf of the following persons, on the resolution in item 4:
   • any of the Company’s KMP whose remuneration details are included in the Remuneration Report; or
   • any of that KMP’s closely related parties, whether as shareholder or proxyholder.

However, these exclusions will not apply where the vote is cast by:
   • a person as proxy for a person who is entitled to vote, provided that the vote is cast in accordance with a direction on the proxy form as to how the proxy is to vote on item 4; or
   • the Chairman of the Annual General Meeting as proxy for a person who is entitled to vote, and the proxy appointment expressly authorises the Chairman to vote undirected proxies on the resolution in item 4 as the Chairman decides.
Explanatory Notes

1. Financial Statements and Reports
   As required by section 317 of the Corporations Act, the Financial Statements of the Company and the Directors’ Report and Auditor’s Report of the Company for the most recent financial year (namely the financial year ended 30 June 2017) will be laid before the Annual General Meeting.

   There is no requirement for a formal resolution on this item. Accordingly, there will be no formal resolution put to the Annual General Meeting in respect of the Financial Statements of the Company and Directors’ Report and Auditor’s Report of the Company for the financial year ended 30 June 2017. However, shareholders will be given a reasonable opportunity at the Annual General Meeting to comment and raise questions on the Financial Statements of the Company and Directors’ Report and Auditor’s Report of the Company. Shareholders will also be able to ask the Company’s Auditor questions.

2. Re-election of Directors
   In accordance with Rule 64 of the Company’s Constitution and Listing Rules 14.4 and 14.5, two directors, Ms Abi Cleland and Mr John Pizzey, will retire by rotation and, being eligible, offer themselves for re-election.

   Details of the Directors seeking re-election are set out below.

   a. Abi Cleland
      (BA, BCom, MBA, GAICD)
      Independent Non-Executive Director
      Abi Cleland has extensive global experience in strategy, M&A, digital and business growth. This has been gained from 20 years of executive roles in the industrial, retail, agriculture and financial services sectors, including with ANZ, Amcor, Incitec Pivot, Caltex and BHP, as well as from smaller entrepreneurial companies.
      Abi currently runs an advisory and management business, Absolute Partners, that focuses on strategy, M&A and building businesses leveraging disruptive changes.
      Currently, Abi is Chairman and Director of Planwise Australia, Director of Swimming Australia and the Managing Director of Absolute Partners.
      Abi has been a Director of the company since February 2014 and is a member of the Audit & Compliance and Human Resources Committees.

   b. John Pizzey
      (BE, (Chem), Dip.Mgt., FTSE)
      Independent Non-Executive Director
      John Pizzey has extensive knowledge of the international resources industry and global environmental management.
      John was formerly Executive Vice President and Group President Primary Products for Alcoa Inc., Chairman of London Metal Exchange, Chairman of Iluka Resources Limited and a Director of Amcor Limited.
      Currently, John is Chairman and Director of Alumina Limited.
      John has been a Director of the Company since December 2013 and is the Chairman of the Human Resources Committee and a member of the Executive and Nomination Committees.

The Directors (other than the relevant Director in relation to their own re-election) consider that each candidate qualifies as an Independent Non-Executive Director and unanimously recommend that shareholders vote in favour of resolutions 2(a) and 2(b). Ms Abi Cleland makes no recommendation in relation to resolution 2(a) due to her interest in the resolution. Mr John Pizzey makes no recommendation in relation to resolution 2(b) due to his interest in the resolution.
3. Incentive grants to Managing Director and Chief Executive Officer

The Company remunerates its Executive KMP (being all KMP other than the Non-Executive Directors) using a combination of fixed and variable plans, with a greater emphasis on variable (at-risk) plans designed to directly incentivise performance.

Under ASX Listing Rule 10.14, shareholder approval is required in order for a Director to acquire securities under an employee incentive scheme. As such, shareholders are asked to approve the following grants under the Company's short term incentive plan ("STI") and long term incentive plan ("LTI") to the Company's Managing Director and Chief Executive Officer, Mr Nigel Garrard, on the terms set out below.

a. Short term incentive grant to Managing Director and Chief Executive Officer

The Company’s STI is designed to reward Executive KMP for the achievement of the Company's key short-term (annual) performance measures, which typically include safety, strategic initiatives and a strong weighting towards financial growth and returns. Two-thirds of an award under the STI is made in the form of a cash payment following the release of the end of year results and the remaining one-third comprises time restricted rights to Orora shares ("Deferred Performance Rights"). Approval is being sought from shareholders for Mr Garrard to participate in the STI and receive Deferred Performance Rights on the terms below for the financial year ending 30 June 2018.

**Overview of the proposed grant:**

<table>
<thead>
<tr>
<th>ENTITLEMENT UNDER THE STI OFFER</th>
<th>The number of Deferred Performance Rights to be granted to Mr Garrard will be calculated:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>a. as a percentage of the total STI award payable following the financial year ending 30 June 2018 (the relevant performance period); and</td>
</tr>
<tr>
<td></td>
<td>b. by reference to the volume-weighted average price (&quot;VWAP&quot;) of the Company's shares for the five trading days up to and including 30 June 2018.</td>
</tr>
</tbody>
</table>

The range of the STI award payable to Mr Garrard is 0-100% of his total fixed remuneration ("TFR") for the financial year ending 30 June 2018. As one-third of any STI award will consist of Deferred Performance Rights, the maximum value of the Deferred Performance Rights granted to Mr Garrard in respect of the financial year ending 30 June 2018 will be $435,000.

Each Deferred Performance Right is a right to acquire one share in the Company, subject to meeting the vesting conditions.

As the VWAP of the Company's shares for the five trading days up to and including the end of the performance period is currently unknown, the maximum number of Deferred Performance Rights (if any) to be granted to Mr Garrard cannot be specified. The method for calculating the number of Deferred Performance Rights to be granted to Mr Garrard is set out below.

The Board has set performance targets for Mr Garrard for the financial year ending 30 June 2018 against which his entitlement to a grant under the STI will be measured. These targets range across financial, strategic, and personal measures, with a safety overlay applied to any STI grant. The weighting attributed to each of these targets is as follows:

<table>
<thead>
<tr>
<th>Target</th>
<th>% Weighting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Earnings per share (&quot;EPS&quot;)</td>
<td>50% (with a stretch weighting of 100%)</td>
</tr>
<tr>
<td>Return on average funds employed (&quot;RoAFE&quot;)</td>
<td>10%</td>
</tr>
<tr>
<td>Average working capital as a % of sales</td>
<td>10%</td>
</tr>
<tr>
<td>Individual objectives</td>
<td>30%</td>
</tr>
</tbody>
</table>

**Safety overlay**

Any STI grant to be made to Mr Garrand on satisfaction of the above targets is also subject to Orora’s performance against a set of safety objectives, measured against key safety metrics. In the event that these safety objectives are not met, any STI grant to Mr Garrand may be reduced by up to 10%.

The Board has chosen the above targets to provide an appropriate balance of financial and non-financial metrics which incentivises performance against the Company's short-term objectives.

In addition, the Board considers that the inclusion of a safety overlay to the entire STI grant, rather than a discrete performance target, provides an increased focus on the safety performance of the Company and aligns with the Company's commitment to zero harm. Safety leadership is an important component of any successful safety culture. Orora's leadership teams have continued to demonstrate their commitment to Orora's safety program and the inclusion of the safety overlay on any STI award to Mr Garrand reflects this commitment to safety.

In conducting its assessment of Mr Garrand’s performance against the above targets, the Board also considers:

a. how Mr Garrand’s performance aligned to the Company’s values;

b. how proactive Mr Garrand was in overcoming challenges in the delivery of the final outcome; and

c. what Mr Garrand’s individual contribution was to the collective outperformance of the Company.
As an illustration only, set out below is an example of the calculation of the number of Deferred Performance Rights that may be granted to Mr Garrard under the STI in respect of the financial year ending 30 June 2018, on the basis that:

a. Mr Garrard’s TFR for the financial year ending 30 June 2018 is $1,305,000; and assuming that:

b. based on his performance during that financial year, the Board determines that Mr Garrard’s STI award will be 70% of his TFR; and
c. the VWAP of Orora shares on ASX during the 5 trading days up to and including 30 June 2018 is $2.86, the number of Deferred Performance Rights to be granted to Mr Garrard would be calculated as follows:

\[
\left(\frac{\left(1,305,000 \times 70\%\right)}{1/3}\right) ÷ 2.86
\]

Based on the above assumptions, and the assumption that Mr Garrard’s stipulated safety objectives under the safety overlay were achieved, Mr Garrard would be granted 106,468 Deferred Performance Rights.

This calculation is shown by way of example only and does not commit the Board to the figures above, including the STI award for Mr Garrard and the VWAP of Orora shares for the relevant period. It is also important to note that the relevant VWAP of Orora shares will directly affect the number of Deferred Performance Rights that may be granted to Mr Garrard.

The Board has overall discretion on the final STI outcome for Mr Garrard, mitigating the risk of unintended award outcomes.

The Company intends that where Deferred Performance Rights vest under the STI, the right to acquire a share in respect of each Deferred Performance Right will be satisfied by the Company arranging to acquire shares on behalf of Mr Garrard on-market; however the Company may instead issue new ordinary shares to Mr Garrard.

<table>
<thead>
<tr>
<th>DATE OF GRANT</th>
<th>If shareholder approval is obtained, and assuming that Mr Garrard becomes eligible to receive a grant under the STI, the Deferred Performance Rights will be granted to Mr Garrard by no later than 30 September 2018.</th>
</tr>
</thead>
<tbody>
<tr>
<td>VESTING PERIOD AND CONDITIONS</td>
<td>The vesting period for the Deferred Performance Rights is two years from the date of the grant. The vesting of Deferred Performance Rights is conditional upon Mr Garrard’s continued employment with the Company throughout this period. Any Deferred Performance Rights that do not vest will lapse. The Board retains discretion to alter the vesting conditions of Deferred Performance Rights where there is a material event (such as an acquisition, divestment or change of control) or other strategic initiative that affects the Company’s capital structure and the relevance of the vesting conditions.</td>
</tr>
<tr>
<td>TRADING RESTRICTIONS</td>
<td>Shares allocated following the vesting of Deferred Performance Rights are not subject to any specific trading restrictions other than the general restrictions set out in the Company’s Share Trading and Minimum Shareholding Policies.</td>
</tr>
<tr>
<td>PRICE PAYABLE ON GRANT OR EXERCISE</td>
<td>No amount is payable in respect of any grant or on the vesting of Deferred Performance Rights.</td>
</tr>
<tr>
<td>CESSATION OF EMPLOYMENT</td>
<td>If Mr Garrard ceases employment with the Company before the Deferred Performance Rights vest, then all unvested Deferred Performance Rights will lapse. However, in limited circumstances, including, for example, retirement, the Board may exercise its discretion to determine the treatment of unvested Deferred Performance Rights and, to the extent permitted by law, may elect to settle any Deferred Performance Rights by way of a cash payment (rather than ordinary shares).</td>
</tr>
<tr>
<td>OTHER REQUIRED INFORMATION</td>
<td>Mr Garrard is the only Director of the Company entitled to participate in the STI. Following approval by shareholders at the 2016 Annual General Meeting, Mr Garrard was granted 119,529 Deferred Performance Rights under the STI in respect of the financial year ended 30 June 2017. The number of Deferred Performance Rights was based on a VWAP of Orora shares for the five trading days up to and including 30 June 2017 of $2.86. In accordance with the terms of the grant, as set out in the Notice of Meeting for the 2016 Annual General Meeting, no amount was paid on the grant and no amount will be payable by Mr Garrard on the vesting of the Deferred Performance Rights to Mr Garrard in respect of the financial year ended 30 June 2017. No other Director has received any securities in the Company under the STI during the financial year ended 30 June 2017. There is no loan scheme in relation to the acquisition of the Deferred Performance Rights issued under the STI.</td>
</tr>
</tbody>
</table>

Notice of Annual General Meeting 2017
Long term incentive grant to Managing Director and Chief Executive Officer

Approval is being sought from shareholders for Mr Garrard to participate in the LTI and receive Options and Performance Rights on the terms below for the financial year ending 30 June 2018.

<table>
<thead>
<tr>
<th># Options</th>
<th># Performance Rights</th>
<th>Vesting (subject to relevant performance conditions being met)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,305,000</td>
<td>342,000</td>
<td>Following the release of the full year results for the financial year ending 30 June 2021 (anticipated to be in August 2021)</td>
</tr>
</tbody>
</table>

Overview of the proposed grant:

ENTITLEMENT UNDER THE LTI OFFER

The Board has invited Mr Garrard to apply for a grant of 1,305,000 Options and 342,000 Performance Rights. Each Option and Performance Right is an option or right (respectively) to acquire one share in the Company. Therefore, the maximum number of shares that may be acquired by Mr Garrard under the grant is 1,305,000 shares (arising from the exercise of vested Options) and 342,000 shares (arising from the vesting of Performance Rights).

The Company intends that where Options and Performance Rights vest under the LTI, the right to acquire a share in respect of each Option and Performance Right will be satisfied by the Company arranging to acquire shares on behalf of Mr Garrard on-market; however the Company may instead issue new ordinary shares to Mr Garrard.

The number of Options to be granted to Mr Garrard is calculated by reference to fair value (using Black-Scholes methodology), with an increase in the value attributed to each Option as determined by the Board. The Board (other than Mr Garrard) each year reviews the appropriateness of the outcome of the calculation of the number of Options to be granted to Mr Garrard. On this occasion, the exercise of discretion by the Board (other than Mr Garrard) results in a reduction in the number of Options which would otherwise be granted to Mr Garrard and the Board has determined that this result is in the best interests of shareholders.

The number of Performance Rights proposed to be awarded to Mr Garrard has been calculated by reference to market value, using the VWAP of the Company's ordinary shares traded on the ASX over the five trading days prior to 30 June 2017. This is the same as the methodology used in the LTI grant that was made to Mr Garrard following approval by shareholders at the 2016 Annual General Meeting.

The value of the grant represents 100% of Mr Garrard's total annual fixed remuneration of $1,305,000, with the proportion of value attributable to Options and Performance Rights being 25% and 75% respectively. The Board considers that this represents a reasonable mix of remuneration which is typical and appropriate for someone in Mr Garrard's position.

DATE OF GRANT

If shareholder approval is obtained, the Options and Performance Rights will be granted to Mr Garrard shortly after the 2017 Annual General Meeting but, in any event, no later than 12 months after the date of the 2017 Annual General Meeting.

PERFORMANCE CONDITIONS FOR THE GRANT

Three performance conditions apply to the LTI grant as detailed below:

<table>
<thead>
<tr>
<th>EPS (with RoAFE gateway) 40% weighting</th>
<th>Relative TSR 40% weighting</th>
<th>Strategic objective 20% weighting</th>
</tr>
</thead>
<tbody>
<tr>
<td>100% Options</td>
<td>20% Performance Rights</td>
<td>80% Performance Rights</td>
</tr>
</tbody>
</table>

100% of Options and 20% of total Performance Rights to be granted to Mr Garrard are subject to the EPS performance condition (with RoAFE gateway). The remaining 80% of total Performance Rights will be split between the relative TSR performance condition (two-thirds) and the strategic objective performance condition (one-third).

EPS Condition (with RoAFE gateway)

40% of any LTI grant to Mr Garrard is subject to an earnings per share ("EPS") condition (based on the Company's compound annual growth rate in EPS over the Performance Period), with a separate minimum gateway based on return on average funds employed ("RoAFE").

RoAFE gateway

In order for any Options or Performance Rights subject to the EPS performance condition to vest, the Company will first need to meet a minimum RoAFE gateway of 12.5%.

RoAFE will be calculated as earnings before interest and tax (post significant items earned by the Company during the relevant reporting period, subject to Board discretion), divided by the average funds employed by the Company as at the 30 June testing date.

RoAFE will be calculated post significant items for the purpose of determining vesting outcomes. Such items may be those relating to strategic initiatives or material events that are outside of normal operational activities, subject to any adjustments that the Board, in its discretion, considers appropriate.
If the RoAFE gateway for the grant is not met in the Performance Period, all Options and Performance Rights subject to this condition will lapse. If the RoAFE gateway for the grant is met in the relevant Performance Period, the relevant Options and Performance Rights will vest in accordance with the EPS vesting schedule below.

**EPS Condition**

EPS measures the earnings generated by the Company attributable to each share on issue. EPS will be calculated based on the Company's net profit after tax excluding significant items, calculated on a constant currency basis (subject to Board discretion) for the relevant financial year, divided by the weighted average number of shares on issue during the year.

The EPS base starting point will be 15.6 cents, being the Company's normalised result for the full financial year ended 30 June 2017, excluding significant items. The Board (excluding Mr Garrard) has reviewed EPS for the purpose of determining the percentage of Performance Rights and Options that will vest under the LTI grant, to reflect the underlying business performance.

The growth in the Company's EPS over the relevant Performance Period (“EPS Growth”) will be calculated as the increase in EPS over the base of 15.6 cents on a constant currency basis. The compound growth in EPS will be expressed as a cumulative percentage.

The percentage of relevant Performance Rights and Options that will vest (subject to achievement of the RoAFE gateway) will be determined as follows, subject to any adjustments for abnormal or unusual profit items that the Board, in its discretion, considers appropriate:

<table>
<thead>
<tr>
<th>EPS Growth</th>
<th>% of Performance Rights/Options that will vest</th>
</tr>
</thead>
<tbody>
<tr>
<td>less than 4%</td>
<td>0%</td>
</tr>
<tr>
<td>at 4%</td>
<td>50%</td>
</tr>
<tr>
<td>between 4% and 8%</td>
<td>straight line vesting between 50% and 100%</td>
</tr>
<tr>
<td>at 8% and above</td>
<td>100%</td>
</tr>
</tbody>
</table>

**Relative TSR condition**

40% of any LTI grant to Mr Garrard is subject to a TSR performance condition. The TSR performance condition measures the growth in the Company’s share price together with the value of dividends declared and other returns of capital paid during the Performance Period compared to companies ranked 30 to 130 (with no exceptions) on the S&P/ASX index [as at 1 July 2017] (“Comparator Group”). The Comparator Group has been selected because the Board considers that this group appropriately reflects Orora’s current market position.

The percentage of Performance Rights subject to the TSR condition that vest under the grant, if any, will be determined by reference to the percentile ranking achieved by the Company over the relevant Performance Period compared to the other entities in the Comparator Group as follows:

<table>
<thead>
<tr>
<th>TSR Performance</th>
<th>% of Performance Rights that will vest</th>
</tr>
</thead>
<tbody>
<tr>
<td>less than 50th percentile</td>
<td>0%</td>
</tr>
<tr>
<td>at 50th percentile</td>
<td>50%</td>
</tr>
<tr>
<td>between 50th and 75th percentile</td>
<td>straight line vesting between 50% and 100%</td>
</tr>
<tr>
<td>at 75th percentile and above</td>
<td>100%</td>
</tr>
</tbody>
</table>

In addition, for any Performance Rights subject to this performance condition to vest, Orora’s absolute TSR over the Performance Period must not be negative. If Orora’s absolute TSR over the Performance Period is negative, no Performance Rights subject to this performance condition will vest, regardless of Orora’s relative performance against the Comparator Group. If Orora's TSR over the Performance Period is not negative, the Performance Rights in the grant will vest in accordance with the TSR vesting schedule above.

The share prices used to calculate the TSR of the Company and each Comparator Group company for the Performance Period will be measured as follows:

a. the opening share price will be the VWAP on the ASX of the Company’s ordinary shares, or the applicable Comparator Group company, for the five trading days leading up to and ending on 30 June 2017; and

b. to ensure the impact of share price volatility is minimised, the closing share price will be the VWAP on the ASX of the Company’s ordinary shares, or the applicable Comparator Group company, for the 20 trading days ending on the last day of the Performance Period.

**Strategic objectives condition**

The remaining 20% of any LTI grant to Mr Garrard will be subject to a strategic objectives condition. The strategic objectives condition measures the Company’s performance over the Performance Period against key aspects of the Company’s strategy, as approved by the Board.
The strategic objectives condition contains objectively-measurable targets which are designed to incentivise performance which is consistent with long term value creation for shareholders. The Board considers that the introduction of a strategic objectives performance condition on any LTI grant to Mr Garrard appropriately recognizes the importance of driving performance in accordance with the Company's long term strategic goals, which in turn creates long term value for shareholders.

The specific quantitative targets under the strategic objectives condition, and the individual weightings given to those targets, are determined by the Board and notified to Mr Garrard. As these targets contain commercially sensitive information, full details are not set out in this Notice of Meeting.

The Board will determine the outcome for the strategic objectives condition having regard to the Company's performance against the quantitative targets following the end of the Performance Period.

**PERFORMANCE PERIOD AND VESTING**
The Performance Period for the grant is from 1 July 2017 through to 30 June 2021.

The EPS performance condition (and RoAFE gateway), TSR performance condition and strategic objectives performance condition for the Options and Performance Rights will be tested shortly after the Performance Period for the grant. Any Options or Performance Rights that do not vest will lapse. No Options will vest unless the price of Orora shares at the time of vesting of Options is greater than the exercise price for those Options. Vested Options will lapse if they are not exercised within five years after vesting.

The Board retains discretion to alter the vesting conditions of Options and Performance Rights where there is a material event (such as an acquisition, divestment or change of control) or other strategic initiative that affects the Company's capital structure and the relevance of the vesting conditions.

**TRADING RESTRICTIONS**
Shares allocated following the exercise of Options and/or the vesting of Performance Rights are not subject to any specific trading restrictions other than the general restrictions set out in the Company's Share Trading and Minimum Shareholding Policies.

**PRICE PAYABLE ON GRANT OR EXERCISE**

Options
No amount is payable by Mr Garrard in respect of the grant of Options. However, vested Options will have an exercise price of $2.86, which is based on the VWAP of the Company's ordinary shares traded on the ASX over the five trading days prior to 30 June 2017.

Performance Rights
No amount is payable by Mr Garrard in respect of the grant or on the vesting of Performance Rights.

**CESSATION OF EMPLOYMENT**
If Mr Garrard ceases employment with the Company before either the Options or Performance Rights vest, then all unvested Options and Performance Rights will lapse.

However, in limited circumstances, including, for example, retirement, the Board may exercise its discretion to determine the treatment of unvested Options and Performance Rights and, to the extent permitted by law, may elect to settle any Options and Performance Rights by way of a cash payment (rather than ordinary shares).

**OTHER REQUIRED INFORMATION**
Mr Garrard is the only Director of the Company entitled to participate in the LTI.

Following approval by shareholders at the 2016 Annual General Meeting, Mr Garrard received a grant under the LTI on 30 October 2016 ("2016 LTI Grant") on the terms set out below:

<table>
<thead>
<tr>
<th># Options</th>
<th># Performance Rights</th>
<th>Vesting (subject to relevant performance conditions being met)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,515,500</td>
<td>355,000</td>
<td>Following the release of the full year results for the financial year ending 30 June 2020 (anticipated to be in August 2020)</td>
</tr>
</tbody>
</table>

Mr Garrard will be required to pay an exercise amount of $2.69 per vested Option under the 2016 LTI Grant. No amount is payable by Mr Garrard on the grant or vesting of the Performance Rights.

No other Director has received any securities in the Company under the LTI during the financial year ended 30 June 2017.

There is no loan scheme in relation to the acquisition of the Options or Performance Rights issued under the LTI.

The Directors (other than Mr Garrard) unanimously recommend that shareholders vote in favour of resolutions 3(a) and 3(b). Mr Garrard makes no recommendation due to his interest in the resolutions.

4. Remuneration Report
The Remuneration Report for the financial year ended 30 June 2017 is set out in the Directors' Report section of the 2017 Annual Report and is also available on the Company's website at www.ororagroup.com.

The Remuneration Report sets out in detail the Company's policy for determining remuneration for Directors and other KMP. It includes information on the elements of remuneration that are performance based, the performance conditions that apply and the methodology used to assess satisfaction of those performance conditions.

The vote on item 4 is advisory only, and does not bind the Directors or the Company. However, shareholders will be given a reasonable opportunity to comment on and ask questions about the Remuneration Report.

Noting that each Director has a personal interest in their own remuneration from the Company, as described in the Remuneration Report, the Directors unanimously recommend that shareholders vote in favour of resolution 4.
1. **Eligibility to vote**

Shareholders will be eligible to vote at the Annual General Meeting if they are registered holders of ordinary shares in the Company as at 7:00pm (Melbourne Time) on 15 October 2017.

2. **Voting methods**

Shareholders can vote in either of two ways:

- by attending the Annual General Meeting and voting in person or by attorney or, in the case of body corporate shareholders, by corporate representative; or
- by appointing a proxy to attend and vote at the Annual General Meeting on their behalf.

Further information regarding each of these voting methods is set out below.

3. **Voting in person**

**Shareholders**

If possible, shareholders should arrive at the Annual General Meeting venue 30 minutes before the time designated for the Annual General Meeting, so that their shareholding can be checked against the Company’s Share Register and attendances noted.

**Attorneys**

A shareholder may appoint an attorney to vote on his or her behalf. For an appointment to be effective for the Annual General Meeting, the instrument effecting the appointment (or a certified copy of it) must be received by the Company at its registered office or by the Company’s Share Registry by no later than 10.30am (Melbourne Time) on 15 October 2017.

**Corporate representatives**

A body corporate which is a shareholder, or which has been appointed as a proxy, may appoint an individual to act as its representative at the Annual General Meeting in accordance with section 250D of the Corporations Act.

If you wish to appoint a body corporate as your proxy, you must specify on the proxy form:

- the full name of the body corporate appointed as proxy; and
- the full name or title of the individual representative of the body corporate who will attend the Annual General Meeting.

Representatives should bring with them satisfactory evidence of their appointment including any authority under which that appointment is signed (unless previously given to the Company).

4. **Voting by proxy**

A shareholder entitled to attend and vote at the Annual General Meeting is entitled to appoint a proxy. A proxy need not be a shareholder of the Company.

The appointment of one or more proxies will not preclude a shareholder from attending and voting at the Annual General Meeting.

A shareholder entitled to cast more than one vote on a resolution may appoint two proxies, in which case the shareholder should specify the proportion or number of votes that each proxy is appointed to exercise. If no proportions or numbers are specified, each proxy may exercise half of the shareholder’s votes. Neither proxy is entitled to vote on a show of hands if both proxies attend the Annual General Meeting.

Shareholders are encouraged to direct their proxies how to vote on each resolution by selecting the ‘for’, ‘against’ or ‘abstain’ box for each item on the proxy form. If a proxy chooses to vote, then he/she must vote in accordance with the directions set out in the proxy appointment form.

If the Chairman of the Annual General Meeting is appointed, or taken to be appointed, as a proxy but the appointment does not direct the proxy how to vote on a resolution, then the Chairman intends to exercise the relevant shareholder’s votes in favour of the relevant resolution (subject to the other provisions of these notes, including the voting exclusions set out in this notice).

In order for the proxy appointment to be valid, completed proxy forms (together with any authority under which the proxy was signed or a certified copy of the authority) must be returned before 10.30am (Melbourne Time) on 15 October 2017 in one of the following four ways:

- by mail: Locked Bag A14, SYDNEY SOUTH, NSW 1235, Australia, or
- online at: www.linkmarketservices.com.au or
- by facsimile: (+612) 9287 0309 or
- by hand (within business hours): 1A Homebush Bay Drive, Rhodes NSW 2138; or Level 12, 680 George Street, SYDNEY, NSW 2000
5. Asking questions at the Annual General Meeting

The Annual General Meeting is intended to give shareholders the opportunity to hear both the Chairman and the Managing Director and Chief Executive Officer talk about the year that has just passed and also give some insight into the Company’s prospects for the year ahead.

Shareholders’ questions are welcome at the Annual General Meeting. In the interests of all present, shareholders are asked to confine questions to matters before the Annual General Meeting that are relevant to shareholders as a whole.

Questions for the Company or the Auditor to respond to at the Annual General Meeting should be submitted online at [www.ororagroup.com](http://www.ororagroup.com) by clicking on “AGM Proxy Voting”, or by sending questions to Orora Limited, C/- Link Market Services Limited, Locked Bag A14, Sydney South, NSW 1235, Australia. Submitting questions in advance will not stop any shareholder from asking questions at the Annual General Meeting should they wish to do so, but will facilitate a considered reply.

Questions should be received by no later than 5.00pm (Melbourne Time) on Tuesday 10 October 2017.

The Company and the Auditor will respond to as many of the more frequently asked questions as possible at the Annual General Meeting. Please note that individual responses will not be sent.

Registered Office

Orora Limited
ABN: 55 004 275 165
109 - 133 Burwood Road
Hawthorn, Victoria 3122, Australia
Telephone: +61 3 9811 7111
Facsimile: +61 3 9811 7171
Website: [www.ororagroup.com](http://www.ororagroup.com)

Orora Share Registry

Link Market Services Limited
Street address:
Tower 4, 727 Collins Street
Melbourne, Victoria 3008, Australia
Postal address:
Locked Bag A14
Sydney South, NSW 1235, Australia
Telephone: +61 1800 207 622
Facsimile: +61 2 9287 0303
Email: orora@linkmarketservices.com.au

Directions to Hawthorn Arts Centre

Travelling by Tram

Catch tram number 16 (Melbourne University to Kew) and alight at stop 73 (Burwood Road/Glenferrie Road).

Travelling by Train

Take any train on the Lilydale, Belgrave or Alamein lines that stop at Glenferrie Railway Station. The Centre is a short walk from Glenferrie Railway Station, alternatively take tram number 16 from Glenferrie Railway Station towards Melbourne University.

The Centre is on the corner of Burwood Road and Glenferrie Road.

Parking

Parking is available behind the Centre off Kent Street. Additional parking is also available a short walk from the Centre off Grace Street and off Wakefield Street. Please note that restrictions apply.